Thursday, 28 May 2020


RegeneRx Chinese heart patent gets nod

08 February 2013 | News | By BioSpectrum Bureau

RegeneRx gets Notice of Allowance from Chinese Patent Office

RegeneRx gets Notice of Allowance from Chinese Patent Office

RegeneRx gets Notice of Allowance from Chinese Patent Office

Singapore: RegeneRx Biopharmaceuticals has received a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease.

RegeneRx Biopharmaceuticals' claims also include uses for restoring heart tissue in those subjects. The patent will expire July 26, 2026.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account